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biomarkers of PsA in PsC patients, most
notably NOTCH2NL, HAT1, CXCL10,
and SETD2, which were associated with
PsA irrespective of clinical differences
between patients. Because of the small
sample size and limited power of the
present study, further validation of these
preliminary findings at the RNA and
protein levels in larger cohorts of PsA
and PsC patients is necessary.
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TO THE EDITOR
Dermatitis herpetiformis (DH), a cuta-
neous manifestation of celiac disease, is
characterized by the deposition of gran-
ular IgA in dermal papillary tips. It has
been shown that transglutaminase 3
(TG3) colocalizes with the IgA in dermal
papillae (Sardy et al., 2002). However,
the additional roles that TG3 may have in
the pathogenesis of DH remain unclear.
Transglutaminase is a family of
enzymes that catalyze posttranslational
modification reactions by transami-
dation, esterification, and hydrolysis
(Iismaa et al., 2009). In celiac disease,
transglutaminase 2 (TG2) has been found
to be crucial in the pathogenesis by
deamidating gliadin and in the
formation of antigenic gliadin-TG2
complexes.
Fibrin (Mustakallio et al., 1970) and
fibronectin (Reitamo et al., 1981) have
been shown to bind in a pattern similar
to IgA in the initial lesions of DH. In our
study of the deposits localized in the
dermal papillae of DH skin, we noted
not only similar localization of fibri-
nogen deposits with the IgA-TG3 com-
plexes but that the stain intensity pattern
of these deposits indicated a similar
quantitative pattern as well. On exami-
nation of biopsies from 13 patients with
DH, photographic overlays of cryosec-
tioned skin stained by direct immuno-
fluorescence for IgA and fibrinogenAccepted article preview online 1 September 2014; published online 25 September 2014
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revealed a homogeneous color blend of
the two different fluorochromes. This
pattern of IgA and fibrinogen staining
was not seen in five biopsies from
patients with IgA vasculitis or in five
biopsies from patients with linear IgA
bullous dermatosis (LABD).
As TG3 colocalizes with IgA in DH
skin, we hypothesized that this enzyme
found in the complexes was active and
responsible for the fibrinogen deposi-
tion. We tested for TGase activity by
the incubation of fluorescein isothiocya-
nate-conjugated cadaverine (Invitrogen,
Eugene, OR) in buffer containing 15 mM
CaCl2 with cryosections of DH skin.
Cadaverine is a primary amine donor
for detecting active transglutaminase in
endogenous substrates (Lajemi et al.,
1997). Microscopy revealed binding of
the labeled cadaverine while overlays
showed colocalization with IgA-TG3
complexes. This binding of cadaverine
could be suppressed with either EDTA
chelation of calcium or with cystamine
(Jeitner et al., 2005) competition as an
amine donor. All control biopsies for
IgA vasculitis and LABD showed no
evidence of TG3 activity by similar
cadaverine binding.
To examine the potential of in silico
binding of soluble fibrinogen by enzy-
matically active IgA-bound TG3, we
incubated DH skin with fluorescein-
labeled human fibrinogen (Invitrogen)
in buffer containing calcium and normal
saline (Figure 1). In all DH biopsies,
labeled fibrinogen bound in a pattern
similar to the IgA deposits. This binding
could also be inhibited by the substitu-
tion of EDTA for CaCl2.
All DH biopsies in addition with the
monkey esophagus (ME) and human
umbilical cord (HUC) tissues were
stained with anti-human TG3 antibody
(Zone et al., 2011) and anti-human TG2
antibody (NeoMarkers, Fremont, CA).
While TG2 was detected in ME and
HUC, it was not noted in DH IgA aggre-
gates, only TG3. We then repeated the
cadaverine cross-linking experiment with
DH skin and ME tissue using the TG2-
specific peptide-based inhibitor TAMRA-
DON (N-(tetramethylrhodaminyl)-DON-
Val-Pro-Leu-Ome) (Figure 2; Zedira,
Darmstadt, Germany; Hausch et al.,
2003). In buffer containing 5mM TAMRA-
DON, cadaverine cross-linking was
completely inhibited in ME and only
minimally decreased in DH skin.
The discovery that TG3 in these
immune complexes retained its enzy-
matic activity even though it was bound
by IgA antibody gave us the opportunity
to test whether dapsone, a primary
medication used in the treatment of this
disease, had any direct effect on TG3
activity. We incubated DH tissue sec-
tions with cadaverine and various con-
centrations of dapsone (1–100mg ml1;
Sigma-Aldrich, St Louis, MO). Dapsone
had no effect on TG3’s enzymatic activ-
ity at levels up to 100mg ml1 spanning
the pharmacologic range of dapsone
concentration.
The presence of granular IgA deposits
in the dermal papillae has long been
recognized as the pathognomonic fea-
ture of DH, yet the method by which
these immune deposits cause inflamma-
tion is unknown. We observed the pre-
sence of fibrinogen in clinical biopsies
of DH in a pattern identical to that of the
well-described IgA-TG3 immunopreci-
pitates. This led us to question the
method of this binding, and to postulate
that the TG3 might be enzymatically
active and might directly lead to fibrino-
gen binding. We are unaware of any
similar circumstance where an enzyme
is antibody bound and secured to tissue,
continues to be enzymatically active,
and may subsequently contribute to
disease pathology. We speculate that
the fibrinogen deposition may have a
key role in the pathogenesis of DH via
the fibrinolytic system.
Several studies offer support to an
active system of fibrinolysis necessary
for blister formation in DH. In 1991,
Cox injected autologous serum intrader-
mally into DH patients and produced
lesions. The addition of heparin, a
thrombin inactivator, or epsilon-amino
Fibrinogen IgA Fibrinogen/IgA
Figure 1. Fluorescein-labeled fibrinogen binds when applied in buffer to IgA aggregates in DH tissue.
Rows a and b are cryoskin sections from the same DH biopsy. Row a, column 1 shows fluorescein-labeled
fibrinogen that has bound to DH skin in the papillary dermis when applied in 25 mM Tris/HCl, pH 8,
with normal saline and 15 mM CaCl2. Row a, column 2 demonstrates direct IgA deposits stained with
rhodamine-tagged goat anti-human IgA. Row a, column 3 shows colocalization of the labeled fibrinogen
with IgA, as denoted by the orange color. Row b, column 1 shows no fluorescein-labeled fibrinogen bound
to DH skin when the CaCl2 was replaced with 5 mM EDTA. Row b, column 2 shows IgA deposits in
DH skin, whereas row b, column 3 shows no colocalization of labeled fibrinogen with IgA as the red
color of the rhodamine tag on the IgA antibody is retained. Both rows were counterstained with
40,6-diamidino-2-phenylindole. Bar¼ 20mm. DH, dermatitis herpetiformis.
TB Taylor et al.
TG3 Present in the IgA Aggregates in Dermatitis Herpetiformis Skin
624 Journal of Investigative Dermatology (2015), Volume 135
caproic acid, an inhibitor of plasmin, to
the serum substantially inhibited lesion
formation (Cox and Friedmann, 1991).
Moreover, heparin has been reported to
be an effective treatment in reported
cases of DH (Tan et al., 1996; Shah
and Ormerod, 2000). Airola in 1995
demonstrated that in early blister
formation in DH patients, urokinase-
type plasminogen activator (uPA) was
present in basal kertinocytes, suggesting
lesion formation by way of an activated
uPA-plasmin pathway (Airola et al.,
1995). This discovery may be of parti-
cular interest as its known wounding of
the skin results in upregulation of uPA
by keratinocytes (Huang et al., 2002)
owing to the loss of tension transmitted
from the underlying dermis (Silver et al.,
2003). Blisters occurring in DH are
typically present in extensor surfaces
such as scalp, elbows, knees, and
buttocks, areas of skin that are daily
subjected to different types of pressure
such as kneeling, sitting, and bending
that may allow for similar protease
production as seen in wounding.
Although the presence of extravascu-
lar fibrinogen deposition in DH is
well documented, its significance is
unknown. Fibrinogen besides being a
clotting factor is an inflammatory pro-
tein with the ability to promote attrac-
tion of T cells, neutrophils, and
macrophages (Davalos and Akassoglou,
2012). The current work demonstrates
the possible mechanism of initiation of
the fibrinolytic pathway in patients with
DH via the fixation of fibrinogen to
dermal tissue by enzymatically active
TG3.
The University of Utah IRB approved
this study and did not require patient
consent for de-identified and otherwise
discarded clinical specimens: the study
was conducted according to the
Declaration of Helsinki Priniples.
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No TAMRA-DONa
b
5 μM TAMRA-DON
Figure 2. The TG2 inhibitor, TAMRA-DON, prevents cadaverine binding to tissue proteins in monkey
esophagus but not in DH skin. Row a shows monkey esophagus sections and row b shows DH skin
sections. Row a, column 1 shows fluorescein-labeled cadaverine that has bound when applied in
buffer without TAMRA-DON. Row a, column 2 demonstrates no bound fluorescein-labeled cadaverine
when applied in buffer with 5mM TAMRA-DON. Row b, column 1 shows fluorescein-labeled cadaverine
that has bound when applied in buffer without TAMRA-DON. Row b, column 2 demonstrates fluorescein-
labeled cadaverine that has bound when applied in buffer with 5mM TAMRA-DON. Both rows were
counterstained with 40,6-diamidino-2-phenylindole. Bar¼20mm. DH, dermatitis herpetiformis;
TG2, transglutaminase 2.
TB Taylor et al.
TG3 Present in the IgA Aggregates in Dermatitis Herpetiformis Skin
www.jidonline.org 625
